TAK
Price
$14.65
Change
-$0.31 (-2.07%)
Updated
Sep 25 closing price
Capitalization
47.5B
34 days until earnings call
ZTS
Price
$141.13
Change
-$0.54 (-0.38%)
Updated
Sep 25 closing price
Capitalization
62.55B
34 days until earnings call
Interact to see
Advertisement

TAK vs ZTS

Header iconTAK vs ZTS Comparison
Open Charts TAK vs ZTSBanner chart's image
Takeda Pharmaceutical
Price$14.65
Change-$0.31 (-2.07%)
Volume$1.88M
Capitalization47.5B
ZOETIS
Price$141.13
Change-$0.54 (-0.38%)
Volume$3.06M
Capitalization62.55B
TAK vs ZTS Comparison Chart in %
Loading...
TAK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
TAK vs. ZTS commentary
Sep 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is TAK is a Buy and ZTS is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 26, 2025
Stock price -- (TAK: $14.65 vs. ZTS: $141.13)
Brand notoriety: TAK: Not notable vs. ZTS: Notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: TAK: 49% vs. ZTS: 100%
Market capitalization -- TAK: $47.5B vs. ZTS: $62.55B
TAK [@Pharmaceuticals: Generic] is valued at $47.5B. ZTS’s [@Pharmaceuticals: Generic] market capitalization is $62.55B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

TAK’s FA Score shows that 2 FA rating(s) are green whileZTS’s FA Score has 2 green FA rating(s).

  • TAK’s FA Score: 2 green, 3 red.
  • ZTS’s FA Score: 2 green, 3 red.
According to our system of comparison, both TAK and ZTS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

TAK’s TA Score shows that 5 TA indicator(s) are bullish while ZTS’s TA Score has 4 bullish TA indicator(s).

  • TAK’s TA Score: 5 bullish, 5 bearish.
  • ZTS’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, TAK is a better buy in the short-term than ZTS.

Price Growth

TAK (@Pharmaceuticals: Generic) experienced а -2.46% price change this week, while ZTS (@Pharmaceuticals: Generic) price change was -4.06% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.66%. For the same industry, the average monthly price growth was +25.27%, and the average quarterly price growth was +68.07%.

Reported Earning Dates

TAK is expected to report earnings on Oct 30, 2025.

ZTS is expected to report earnings on Nov 04, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (-0.66% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZTS($62.5B) has a higher market cap than TAK($47.5B). TAK has higher P/E ratio than ZTS: TAK (50.58) vs ZTS (24.29). TAK YTD gains are higher at: 10.733 vs. ZTS (-12.527). TAK has higher annual earnings (EBITDA): 1.13T vs. ZTS (4.02B). TAK has more cash in the bank: 419B vs. ZTS (1.44B). ZTS has less debt than TAK: ZTS (6.79B) vs TAK (4.51T). TAK has higher revenues than ZTS: TAK (4.48T) vs ZTS (9.39B).
TAKZTSTAK / ZTS
Capitalization47.5B62.5B76%
EBITDA1.13T4.02B27,992%
Gain YTD10.733-12.527-86%
P/E Ratio50.5824.29208%
Revenue4.48T9.39B47,736%
Total Cash419B1.44B29,199%
Total Debt4.51T6.79B66,353%
FUNDAMENTALS RATINGS
TAK vs ZTS: Fundamental Ratings
TAK
ZTS
OUTLOOK RATING
1..100
6053
VALUATION
overvalued / fair valued / undervalued
1..100
5
Undervalued
33
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
8919
PRICE GROWTH RATING
1..100
6064
P/E GROWTH RATING
1..100
3185
SEASONALITY SCORE
1..100
8575

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TAK's Valuation (5) in the Pharmaceuticals Major industry is in the same range as ZTS (33) in the Pharmaceuticals Generic industry. This means that TAK’s stock grew similarly to ZTS’s over the last 12 months.

TAK's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as ZTS (100) in the Pharmaceuticals Generic industry. This means that TAK’s stock grew similarly to ZTS’s over the last 12 months.

ZTS's SMR Rating (19) in the Pharmaceuticals Generic industry is significantly better than the same rating for TAK (89) in the Pharmaceuticals Major industry. This means that ZTS’s stock grew significantly faster than TAK’s over the last 12 months.

TAK's Price Growth Rating (60) in the Pharmaceuticals Major industry is in the same range as ZTS (64) in the Pharmaceuticals Generic industry. This means that TAK’s stock grew similarly to ZTS’s over the last 12 months.

TAK's P/E Growth Rating (31) in the Pharmaceuticals Major industry is somewhat better than the same rating for ZTS (85) in the Pharmaceuticals Generic industry. This means that TAK’s stock grew somewhat faster than ZTS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
TAKZTS
RSI
ODDS (%)
Bearish Trend 3 days ago
61%
Bullish Trend 3 days ago
74%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
38%
Bullish Trend 3 days ago
49%
Momentum
ODDS (%)
Bearish Trend 3 days ago
52%
Bearish Trend 3 days ago
61%
MACD
ODDS (%)
Bearish Trend 3 days ago
41%
Bearish Trend 3 days ago
53%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
49%
Bearish Trend 3 days ago
58%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
40%
Bearish Trend 3 days ago
59%
Advances
ODDS (%)
Bullish Trend 16 days ago
43%
Bullish Trend 22 days ago
57%
Declines
ODDS (%)
Bearish Trend 9 days ago
45%
Bearish Trend 3 days ago
57%
BollingerBands
ODDS (%)
Bearish Trend 5 days ago
56%
Bullish Trend 3 days ago
58%
Aroon
ODDS (%)
Bullish Trend 3 days ago
36%
Bearish Trend 3 days ago
64%
View a ticker or compare two or three
Interact to see
Advertisement
TAK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
THTA15.130.01
+0.07%
SoFi Enhanced Yield ETF
BIT13.46-0.07
-0.52%
BLACKROCK MULTI-SECTOR Income TRUST
SCHB25.39-0.14
-0.53%
Schwab US Broad Market ETF™
BFOR80.40-0.76
-0.94%
Barron's 400 ETF
FLSA34.02-0.64
-1.85%
Franklin FTSE Saudi Arabia ETF

TAK and

Correlation & Price change

A.I.dvisor indicates that over the last year, TAK has been loosely correlated with HLN. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if TAK jumps, then HLN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TAK
1D Price
Change %
TAK100%
-2.00%
HLN - TAK
42%
Loosely correlated
-1.69%
ZTS - TAK
30%
Poorly correlated
-0.37%
RDY - TAK
24%
Poorly correlated
-2.01%
EOLS - TAK
24%
Poorly correlated
-1.64%
EVO - TAK
23%
Poorly correlated
-4.20%
More

ZTS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZTS has been loosely correlated with VTRS. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ZTS jumps, then VTRS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZTS
1D Price
Change %
ZTS100%
-0.37%
VTRS - ZTS
48%
Loosely correlated
-2.32%
ELAN - ZTS
46%
Loosely correlated
+0.91%
PAHC - ZTS
41%
Loosely correlated
-0.55%
HLN - ZTS
38%
Loosely correlated
-1.69%
AMRX - ZTS
38%
Loosely correlated
-1.03%
More